Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 328

1.

Watery stools and metabolic acidosis.

Ferrari MC, Miele L, Guidi L, Rindi G, Rocchi C, Castaldi P, Alfieri S, Gasbarrini A, Grieco A, Rapaccini G.

Intern Emerg Med. 2017 Apr 5. doi: 10.1007/s11739-017-1656-2. [Epub ahead of print] No abstract available.

PMID:
28382558
2.

Liver transplantation for drug-induced acute liver failure.

Biolato M, Araneo C, Marrone G, Liguori A, Miele L, Ponziani FR, Gasbarrini A, Grieco A.

Eur Rev Med Pharmacol Sci. 2017 Mar;21(1 Suppl):37-45.

3.

Fatty liver and drugs: the two sides of the same coin.

Miele L, Liguori A, Marrone G, Biolato M, Araneo C, Vaccaro FG, Gasbarrini A, Grieco A.

Eur Rev Med Pharmacol Sci. 2017 Mar;21(1 Suppl):86-94.

4.

Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind.

Marrone G, Vaccaro FG, Biolato M, Miele L, Liguori A, Araneo C, Ponziani FR, Mores N, Gasbarrini A, Grieco A.

Eur Rev Med Pharmacol Sci. 2017 Mar;21(1 Suppl):122-134.

5.

Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.

Gnani D, Romito I, Artuso S, Chierici M, De Stefanis C, Panera N, Crudele A, Ceccarelli S, Carcarino E, D'Oria V, Porru M, Giorda E, Ferrari K, Miele L, Villa E, Balsano C, Pasini D, Furlanello C, Locatelli F, Nobili V, Rota R, Leonetti C, Alisi A.

Cell Death Differ. 2017 Mar 24. doi: 10.1038/cdd.2017.34. [Epub ahead of print]

PMID:
28338656
6.

AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions.

Italian Association for the Study of the Liver (AISF)., Lonardo A, Nascimbeni F, Targher G, Bernardi M, Bonino F, Bugianesi E, Casini A, Gastaldelli A, Marchesini G, Marra F, Miele L, Morisco F, Petta S, Piscaglia F, Svegliati-Baroni G, Valenti L, Bellentani S.

Dig Liver Dis. 2017 Jan 23. pii: S1590-8658(17)30151-2. doi: 10.1016/j.dld.2017.01.147. [Epub ahead of print]

PMID:
28215516
7.

The NAFL Risk Score: A simple scoring model to predict 4-y risk for non-alcoholic fatty liver.

Zhou YJ, Zheng JN, Liu WY, Miele L, Vitale A, Van Poucke S, Zou TT, Fang DH, Shen S, Zhang DC, Zheng MH.

Clin Chim Acta. 2017 Jan 19;468:17-24. doi: 10.1016/j.cca.2017.01.021. [Epub ahead of print]

PMID:
28111272
8.

Serum alkaline phosphatase, a risk factor for non-alcoholic fatty liver, but only for women in their 30s and 40s: evidence from a large cohort study.

Zhou YJ, Zou H, Zheng JN, Zou TT, Vitale A, Miele L, Van Poucke S, Liu WY, Shen S, Zhang DC, Shi KQ, Zheng MH.

Expert Rev Gastroenterol Hepatol. 2017 Mar;11(3):269-276. doi: 10.1080/17474124.2017.1283984. Epub 2017 Jan 27.

PMID:
28095261
9.

Advancing the Science of Health Disparities Through Research on the Social Determinants of Health.

Fouad MN, Oates GR, Scarinci IC, Demark-Wahnefried W, Hamby BW, Bateman LB, Estrada JJ, Payton M, Sims M, Miele L, Partridge EE.

Am J Prev Med. 2017 Jan;52(1S1):S1-S4. doi: 10.1016/j.amepre.2016.09.032. No abstract available.

10.

Pathophysiology of Non Alcoholic Fatty Liver Disease.

Petta S, Gastaldelli A, Rebelos E, Bugianesi E, Messa P, Miele L, Svegliati-Baroni G, Valenti L, Bonino F.

Int J Mol Sci. 2016 Dec 11;17(12). pii: E2082. Review.

11.

Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression.

Sorrentino C, Miele L, Porta A, Pinto A, Morello S.

Oncotarget. 2016 Sep 27;7(39):64274-64288. doi: 10.18632/oncotarget.11729.

12.

Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD).

Liu J, Zheng S, Akerstrom VL, Yuan C, Ma Y, Zhong Q, Zhang C, Zhang Q, Guo S, Ma P, Skripnikova EV, Bratton MR, Pannuti A, Miele L, Wiese TE, Wang G.

J Med Chem. 2016 Sep 8;59(17):8134-40. doi: 10.1021/acs.jmedchem.6b00753. Epub 2016 Aug 29.

PMID:
27529700
13.

The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease.

Sanduzzi Zamparelli M, Compare D, Coccoli P, Rocco A, Nardone OM, Marrone G, Gasbarrini A, Grieco A, Nardone G, Miele L.

Int J Mol Sci. 2016 Jul 29;17(8). pii: E1225. doi: 10.3390/ijms17081225. Review.

14.

Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders.

Gulli F, Basile U, Gragnani L, Fognani E, Napodano C, Colacicco L, Miele L, De Matthaeis N, Cattani P, Zignego AL, Rapaccini GL.

Dig Liver Dis. 2016 Aug;48(8):927-33. doi: 10.1016/j.dld.2016.05.013. Epub 2016 May 24.

PMID:
27289333
15.

High prevalence of luminal B breast cancer intrinsic subtype in Colombian women.

Serrano-Gomez SJ, Sanabria-Salas MC, Hernández-Suarez G, García O, Silva C, Romero A, Mejía JC, Miele L, Fejerman L, Zabaleta J.

Carcinogenesis. 2016 Jul;37(7):669-76. doi: 10.1093/carcin/bgw043. Epub 2016 Apr 16.

PMID:
27207651
16.

Notch Signaling in Neuroendocrine Tumors.

Crabtree JS, Singleton CS, Miele L.

Front Oncol. 2016 Apr 14;6:94. doi: 10.3389/fonc.2016.00094. eCollection 2016. Review.

17.

Molecular Analysis of Central Nervous System Disease Spectrum in Childhood Acute Lymphoblastic Leukemia.

Hicks C, Sitthi-Amorn J, Douglas J, Ramani R, Miele L, Vijayakumar V, Karlson C, Chipeta J, Megason G.

Clin Med Insights Oncol. 2016 Mar 14;10:5-15. doi: 10.4137/CMO.S18180. eCollection 2016.

18.

Serum From Advanced Heart Failure Patients Promotes Angiogenic Sprouting and Affects the Notch Pathway in Human Endothelial Cells.

Pannella M, Caliceti C, Fortini F, Aquila G, Vieceli Dalla Sega F, Pannuti A, Fortini C, Morelli MB, Fucili A, Francolini G, Voltan R, Secchiero P, Dinelli G, Leoncini E, Ferracin M, Hrelia S, Miele L, Rizzo P.

J Cell Physiol. 2016 Dec;231(12):2700-10. doi: 10.1002/jcp.25373. Epub 2016 Apr 4.

PMID:
26987674
19.

Aberrant activation of canonical Notch1 signaling in the mouse uterus decreases progesterone receptor by hypermethylation and leads to infertility.

Su RW, Strug MR, Jeong JW, Miele L, Fazleabas AT.

Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2300-5. doi: 10.1073/pnas.1520441113. Epub 2016 Feb 8.

20.

Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.

Eslam M, Mangia A, Berg T, Chan HL, Irving WL, Dore GJ, Abate ML, Bugianesi E, Adams LA, Najim MA, Miele L, Weltman M, Mollison L, Cheng W, Riordan S, Fischer J, Romero-Gomez M, Spengler U, Nattermann J, Rahme A, Sheridan D, Booth DR, McLeod D, Powell E, Liddle C, Douglas MW, van der Poorten D, George J; International Liver Disease Genetics Consortium..

Hepatology. 2016 Jul;64(1):34-46. doi: 10.1002/hep.28475. Epub 2016 Mar 30.

PMID:
26822232

Supplemental Content

Support Center